Cargando…

The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography

Detalles Bibliográficos
Autores principales:	Veerman, Hans, Donswijk, Maarten, Bekers, Elise, Bodar, Yves J.L., Meijer, Dennie, van Moorselaar, R. Jeroen A., Oprea‐Lager, Daniela E., van der Noort, Vincent, van Leeuwen, Pim J., Vis, André N., van der Poel, Henk G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828411/ https://www.ncbi.nlm.nih.gov/pubmed/36117468 http://dx.doi.org/10.1111/bju.15896

Ejemplares similares

The clinical characteristics of patients with primary non‐prostate‐specific membrane antigen‐expressing prostate cancer on preoperative positron emission tomography/computed tomography
por: Veerman, Hans, et al.
Publicado: (2021)

Standardised uptake values as determined on prostate‐specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer
por: Bodar, Yves J.L., et al.
Publicado: (2022)

Higher Preoperative Maximum Standardised Uptake Values (SUV(max)) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [(68)Ga]Ga-PSMA-11 and [(18)F]DCFPyL Positron Emission Tomography/Computed Tomography
por: de Bie, Katelijne C. C., et al.
Publicado: (2023)

Predicting early outcomes in patients with intermediate‐ and high‐risk prostate cancer using prostate‐specific membrane antigen positron emission tomography and magnetic resonance imaging
por: Meijer, Dennie, et al.
Publicado: (2021)

External Validation of Two Nomograms Developed for (68)Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer (18)F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
por: Luiting, Henk B., et al.
Publicado: (2021)

Comment on Rosenzweig et al. Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates. J. Pers. Med. 2022, 12, 410
por: Veerman, Hans, et al.
Publicado: (2022)

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
por: Luining, Wietske I., et al.
Publicado: (2022)

Distribution of prostate cancer recurrences on gallium‐68 prostate‐specific membrane antigen ((68)Ga‐PSMA) positron‐emission/computed tomography after radical prostatectomy with pathological node‐positive extended lymph node dissection
por: Huits, Thijs H., et al.
Publicado: (2020)

Management impact of (18)F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study
por: Meijer, Dennie, et al.
Publicado: (2021)

Detection of prostate cancer with (18)F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial
por: Bodar, Y. J. L., et al.
Publicado: (2020)

Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study
por: Donswijk, Maarten L., et al.
Publicado: (2020)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature
por: Luiting, Henk B., et al.
Publicado: (2019)

(68)Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: first-in-man series
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer
por: Tateishi, Ukihide
Publicado: (2020)

Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET/CT: a single-centre retrospective study
por: Donswijk, Maarten L., et al.
Publicado: (2022)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia
por: Song, Rachel, et al.
Publicado: (2022)

Prostate-specific Membrane Antigen Positron Emission Tomography, Not Conventional Imaging, Should Be Performed for Primary Staging of High-risk Prostate Cancer: Con
por: van der Poel, Henk
Publicado: (2021)

Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
por: Minn, Il, et al.
Publicado: (2019)

Comparison of Ga-68 PSMA positron emission tomography/computerized tomography with Tc-99m MDP bone scan in prostate cancer patients
por: USLU-BEŞLİ, Lebriz, et al.
Publicado: (2019)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis
por: Woo, Sungmin, et al.
Publicado: (2020)

(68)Ga-Prostate-specific membrane antigen (PSMA) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis
por: Matushita, Cristina S., et al.
Publicado: (2020)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
por: Privé, Bastiaan M., et al.
Publicado: (2021)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
por: Privé, Bastiaan M., et al.
Publicado: (2020)

Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels
por: Meijer, Dennie, et al.
Publicado: (2019)

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
por: Fanti, Stefano, et al.
Publicado: (2020)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
por: Leung, Kevin H., et al.
Publicado: (2022)

Comparison of (68)Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer
por: Van Damme, Julien, et al.
Publicado: (2021)

Day-to-day variability of [(68)Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Meningioma uptake of (68)Gallium-PSMA-11 as a pitfall on positron emission tomography/computer tomography
por: Courtney, Michael, et al.
Publicado: (2021)

PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer
por: Meher, Niranjan, et al.
Publicado: (2023)

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy
por: Rybalov, Maxim, et al.
Publicado: (2014)

Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Editorial Comment: (68)Ga-Prostate-specific membrane antigen (PSMA) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis
por: Zequi, Stênio de C.
Publicado: (2021)

A DROP-IN beta probe for robot-assisted (68)Ga-PSMA radioguided surgery: first ex vivo technology evaluation using prostate cancer specimens
por: Collamati, Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3blb5pf5vfabn6snp4pj0vc4d5